How to Get Vyleesi (Bremelanotide) in Massachusetts

What Vyleesi Is and Why the Prescription Process Matters

Bremelanotide (Vyleesi) is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women [1]. It works at MC1R and MC4R receptors in the central nervous system to modulate sexual desire pathways, a mechanism entirely different from hormonal therapies or phosphodiesterase inhibitors [2]. Because it acts centrally rather than genitally, prescribers must confirm the diagnosis meets DSM-5 criteria before writing a prescription.

The FDA label restricts use to premenopausal women and carries a contraindication for patients with cardiovascular disease, because bremelanotide transiently raises mean arterial pressure by approximately 2 mmHg and decreases heart rate by approximately 0.7 beats per minute for up to 12 hours after dosing [1]. Blood pressure must be documented as controlled before the first prescription is issued.

Massachusetts adds no state-specific restrictions beyond federal requirements, which simplifies access compared with some other states. Still, the process has defined steps: diagnosis, prescriber visit, insurance or cash-pay decision, and pharmacy fulfillment. Each step is covered in detail below.

Step 1. Confirm the HSDD Diagnosis

HSDD is defined as persistently low sexual desire that causes marked distress or interpersonal difficulty and cannot be explained by another medical condition, relationship context, or medication effect [3]. The DSM-5 combines previous HSDD and Female Sexual Arousal Disorder into Female Sexual Interest/Arousal Disorder (FSIAD), but the FDA labeling and clinical trials for bremelanotide still use the HSDD terminology for the specific acquired, generalized subtype [3].

Two validated screening tools are commonly used in clinical practice. The Female Sexual Function Index (FSFI), a 19-item questionnaire, has a total score cutoff of 26.55; scores below that threshold are associated with sexual dysfunction [4]. The Female Sexual Distress Scale-Revised (FSDS-R) measures distress specifically; a score of 11 or higher on the total scale suggests clinically meaningful distress [5]. Most Massachusetts telehealth platforms and outpatient clinicians administer both at the intake visit.

Before attributing low desire to HSDD, the prescriber should review thyroid function (TSH), prolactin, and total testosterone, because hypothyroidism, hyperprolactinemia, and androgen deficiency each mimic HSDD symptomatically [6]. A complete medication list matters too. SSRIs, SNRIs, combined oral contraceptives, and antihypertensives all suppress libido at rates that can exceed 30 to 40 percent in longitudinal studies [7].

Step 2. Choose a Massachusetts-Licensed Prescriber

Any Massachusetts-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) operating within their scope of practice may prescribe bremelanotide. NPs in Massachusetts have full independent prescribing authority after completing required collaborative practice requirements under M.G.L. c. 112, § 80E [8]. PAs may prescribe under a supervising physician agreement.

Gynecologists, women's health NPs, and sexual medicine specialists are natural fits, but primary care providers write a significant share of Vyleesi prescriptions nationally. The prescriber does not need to be a specialist; they simply need to document a qualifying diagnosis.

Telehealth Is Fully Permitted in Massachusetts

Massachusetts permanently authorized telehealth prescribing for non-controlled substances after the COVID-19 public health emergency extensions were codified. Bremelanotide is not a controlled substance, so a prescriber with a Massachusetts license may conduct a synchronous audio-video visit, document the HSDD diagnosis, confirm contraindications are absent, and transmit the prescription electronically to any Massachusetts-licensed pharmacy. No in-person visit is required by state law [8].

A synchronous visit (live video or phone) is the standard for new prescriptions. Asynchronous telehealth (questionnaire-only) may be used by some platforms but carries higher risk of missing contraindications such as uncontrolled hypertension or a personal history of cardiovascular disease, conditions the FDA label flags explicitly [1].

Step 3. Understand the Clinical Evidence Supporting the Prescription

The key RECONNECT program consisted of two identically designed Phase 3 randomized controlled trials. Pooled, the two trials enrolled 1,267 premenopausal women with acquired, generalized HSDD [9]. Participants received bremelanotide 1.75 mg SC or placebo as needed over 24 weeks. The co-primary endpoints were change from baseline in the FSFI desire domain score and the FSDS-R item 13 (distress score).

In the pooled RECONNECT analysis, bremelanotide produced a statistically significant improvement in the FSFI desire domain score (mean change +0.6 versus +0.2 for placebo; P<0.001) and a significant reduction in FSDS-R distress score (mean change -1.2 versus -0.8 for placebo; P<0.001) [9]. Roughly 25 percent of treated women reported feeling much or very much improved on the Patient Global Impression of Improvement scale versus 17 percent on placebo [9]. These effect sizes are modest in absolute terms, a point the FDA briefing document acknowledged openly, which is why patient selection and counseling about realistic outcomes matters before prescribing [1].

Nausea was the most common adverse event, occurring in approximately 40 percent of bremelanotide-treated subjects versus 1 percent on placebo, typically lasting about one hour after injection [9]. Pre-treating with ondansetron 4 mg orally 30 minutes before the injection is an off-label but frequently used mitigation strategy.

The American College of Obstetricians and Gynecologists (ACOG) issued guidance noting: "Bremelanotide may be offered to premenopausal women with acquired, generalized HSDD after thorough discussion of benefits and risks, including the transient blood pressure increase and high rate of nausea" [10].

Step 4. Labs and Baseline Measurements Required in Massachusetts

No Massachusetts-specific statute mandates particular labs before bremelanotide, but the FDA label and standard-of-care practice require baseline blood pressure measurement before the first dose and after the first dose [1]. The prescriber must document that the patient does not have uncontrolled hypertension (defined as resting BP above 130/80 mmHg per the 2017 ACC/AHA guidelines) or known cardiovascular disease [11].

Standard pre-prescription workup at most Massachusetts practices includes:

• Blood pressure reading (in-clinic or validated home monitor with transmission to provider)
• TSH to exclude hypothyroidism
• Prolactin if menstrual irregularity is present
• Complete medication reconciliation for libido-suppressing drugs
• FSFI and FSDS-R scored questionnaires

Testosterone testing is optional at initial workup but helps differentiate androgen deficiency from true central HSDD [6]. If free testosterone is low-normal or below the reference range, some clinicians prefer a trial of testosterone optimization before adding bremelanotide, given lower cost and more favorable tolerability profiles for testosterone therapy [12].

Step 5. Insurance Coverage and Prior Authorization in Massachusetts

MassHealth (Medicaid)

MassHealth covers bremelanotide for HSDD in premenopausal women with a prior authorization (PA). The PA criteria generally require documentation of all of the following: a DSM-5-consistent HSDD diagnosis, absence of a contributing medical or psychiatric condition that is untreated, a trial or evaluation of at least one alternative intervention such as counseling or lubricants, and a documented blood pressure reading within normal limits [13].

The PA process typically takes 3 to 7 business days once the prescriber submits the request with supporting clinical notes. If denied, the prescriber can request a peer-to-peer review or file a Level 1 appeal within 30 days.

Commercial Insurance

Coverage varies by plan. Many commercial plans in Massachusetts treat bremelanotide as a Tier 3 specialty drug with step therapy requirements, most commonly a documented trial of flibanserin (Addyi) or a documented contraindication to it. Flibanserin requires alcohol abstinence and is contraindicated with strong CYP3A4 inhibitors, so contraindications are real and documentable [14]. Providing this documentation up front shortens the PA timeline.

Cash-Pay Pricing

The retail list price for Vyleesi is approximately $900 to $1,000 per single-dose auto-injector kit. Palatin Technologies and authorized specialty pharmacies offer savings programs. Patients with commercial insurance may reduce out-of-pocket costs to as low as $0 per month through manufacturer copay assistance cards, which currently exclude federal and state government insurance beneficiaries [15].

Step 6. Pharmacy Options in Massachusetts

Retail and Specialty Pharmacies

Vyleesi is stocked at specialty pharmacies rather than standard retail chains in most cases. Walgreens Specialty Pharmacy, CVS Specialty, and independent compounding-capable pharmacies are common dispensing points in Massachusetts. The prescriber or telehealth platform typically coordinates the specialty pharmacy channel.

503A Compounding Pharmacies

A 503A pharmacy is a traditional state-licensed compounding pharmacy operating under USP 797 sterile compounding standards [16]. Licensed 503A pharmacies in Massachusetts may compound bremelanotide for individual patients when a valid patient-specific prescription exists and there is a documented clinical reason for compounding (such as cost, or a documented allergy to an excipient in the commercial product). Bremelanotide is not currently on the FDA's 503B outsourcing facility category list, so it occupies a legally gray area for large-scale compounding; 503A patient-specific compounding is the more defensible route [16].

Patients choosing the compounded route should verify that the pharmacy holds a current Massachusetts Pharmacy Board license (searchable at the Massachusetts Board of Registration in Pharmacy) and that sterile compounds are produced under USP 797 standards with documented potency testing [17].

Transferring an Out-of-State Prescription

Massachusetts accepts transferred prescriptions for non-controlled substances from out-of-state pharmacies, provided the prescriber holds an active Massachusetts license or the prescription was written by an out-of-state prescriber who is authorized to prescribe in Massachusetts under a valid telehealth relationship [8]. If the original prescription was written by a provider not licensed in Massachusetts, the patient needs a new prescription from a Massachusetts-licensed provider before any Massachusetts pharmacy can legally dispense.

Step 7. How to Self-Administer Bremelanotide

The commercial auto-injector delivers 1.75 mg bremelanotide subcutaneously. Injection sites are the abdomen or thigh; the upper arm is a third option [1]. The manufacturer recommends rotating sites to reduce local reactions, which occur in approximately 17 percent of patients and typically resolve within a day [9].

Injection timing is 45 minutes before anticipated sexual activity. The dose should not be repeated within 24 hours, and the FDA label advises against exceeding eight doses per month due to a dose-dependent risk of hyperpigmentation of the face, gums, and breasts with chronic high-frequency use [1]. Hyperpigmentation was observed in the RECONNECT long-term safety extension and resolved slowly after discontinuation [9].

Practical injection tips that reduce nausea:

1. Administer ondansetron 4 mg orally 30 minutes before the injection (discuss with prescriber first).
2. Eat a light meal 1 to 2 hours before dosing; injecting on a completely empty stomach worsens nausea.
3. Stay hydrated.
4. Remain seated or lying down for 30 to 60 minutes after the injection, as transient dizziness is reported in roughly 11 percent of users [9].

Step 8. Monitoring and Follow-Up

The prescriber should schedule a follow-up visit at 4 to 8 weeks after the first fill to assess response, blood pressure trend, and tolerability. The FSFI desire domain and FSDS-R item 13 are useful at follow-up to quantify change objectively [4, 5]. Blood pressure should be rechecked; the label states that if a patient experiences a significant BP increase, the prescriber should evaluate the cause before continuing [1].

If nausea is intolerable despite antiemetic pre-treatment, or if BP rises above 130/80 mmHg repeatedly, discontinuation is appropriate. Response rates in RECONNECT suggest that roughly 25 percent of patients experience a meaningful improvement [9]; patients who do not notice a subjective difference after three to four uses may reasonably discontinue.

Comparing Bremelanotide to Flibanserin in Massachusetts Practice

Flibanserin (Addyi) is the only other FDA-approved pharmacologic treatment for HSDD in premenopausal women [14]. It is a non-hormonal serotonin 1A agonist/2A antagonist taken daily at 100 mg orally at bedtime. The two drugs differ substantially in administration, mechanism, and side-effect profile.

Bremelanotide is dosed as needed, which suits patients whose low desire is situational or infrequent. Flibanserin requires daily administration and takes 4 to 8 weeks to show effect, which may affect adherence [14]. Flibanserin carries a black-box warning for severe hypotension and loss of consciousness with alcohol use; bremelanotide carries no alcohol interaction warning [1, 14].

In a 2021 meta-analysis published in the Journal of Sexual Medicine, both drugs showed statistically significant but modest improvements over placebo on FSFI desire domain scores, with no head-to-head superiority established between them [18]. Prescriber and patient preference, insurance formulary position, and tolerability often determine the choice.

Timeline From First Telehealth Visit to First Dose in Massachusetts

Most patients move through the following sequence:

• Day 1: Complete intake questionnaire and FSFI/FSDS-R forms online; schedule synchronous telehealth visit.
• Day 1 to 2: Synchronous video visit with Massachusetts-licensed prescriber. Baseline blood pressure documented (home monitor acceptable if validated). Prescription transmitted electronically.
• Day 2 to 4: Insurance PA submitted if applicable. Cash-pay prescriptions often processed same day.
• Day 4 to 7: Pharmacy receives PA approval or processes cash-pay order. Specialty pharmacy ships overnight or 2-day to a Massachusetts address.
• Day 5 to 10: Patient receives auto-injector kit, reviews injection training materials, administers first dose.

The MassHealth PA step is the most common source of delay. Commercial PA can be faster when the prescriber submits documentation proactively rather than waiting for the plan to request it.

Special Populations and Contraindications

Bremelanotide is contraindicated in patients with known cardiovascular disease, including uncontrolled hypertension, history of myocardial infarction, unstable angina, or heart failure [1]. Women with darker Fitzpatrick skin types (IV through VI) face a higher absolute risk of facial hyperpigmentation with repeated use and should be counseled specifically on limiting monthly dose frequency [9].

Bremelanotide is not approved or studied in postmenopausal women. While some clinicians prescribe it off-label in this population, MassHealth and most commercial plans will not cover it for that indication, and the evidentiary base is thin [9]. Pregnancy is an absolute contraindication; a negative pregnancy test before the first prescription is standard practice [1]. The FDA Pregnancy Surveillance Program has received reports of inadvertent exposure; outcomes data remain limited [1].

No dose adjustment is required for mild to moderate renal or hepatic impairment. Severe hepatic impairment (Child-Pugh Class C) is a contraindication because bremelanotide is extensively metabolized by enzymatic hydrolysis, and exposure increases substantially in severe liver disease [1].